Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis
MCARH109(一种靶向G蛋白偶联受体C类5成员D (GPRC5D) 的嵌合抗原受体T细胞疗法)治疗多发性骨髓瘤的I期临床试验:最新分析
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-24-01785
Jurgens, Eric M; Firestone, Ross S; Chaudhari, Jagrutiben; Hosszu, Kinga; Devlin, Sean M; Shah, Urvi A; Landa, Jonathan; McAvoy, Devin P; Lesokhin, Alexander M; Korde, Neha; Hassoun, Hani; Tan, Carlyn R; Hultcrantz, Malin; Shah, Gunjan L; Landau, Heather J; Chung, David J; Scordo, Michael; Eren, Ozgur Can; Dogan, Ahmet; Giralt, Sergio A; Park, Jae H; Rivière, Isabelle; Brentjens, Renier J; Smith, Eric L; Wang, Xiuyan; Usmani, Saad Z; Mailankody, Sham
T细胞
多发性骨髓瘤
信号转导
T细胞
骨髓瘤
ARH
细胞生物学
免疫/内分泌